Last reviewed · How we verify
GP681 Powder for Oral Suspension
At a glance
| Generic name | GP681 Powder for Oral Suspension |
|---|---|
| Also known as | Test Treatment |
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (PHASE1)
- Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: